Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its Board of Directors has authorized an extension through July 31, 2022 of Lantern’s existing share repurchase program to acquire up to $7 million of the Company’s common stock.
‘New [National Transportation Safety Board] chief warns against false claims on automated driving’ -Automotive News Report
https://www.autonews.com/regulation-safety/new-ntsb-chief-warns-against-false-claims-automated-driving
